Your browser doesn't support javascript.
loading
Interleukin-7 receptor α mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.
Almeida, Afonso R M; Neto, João L; Cachucho, Ana; Euzébio, Mayara; Meng, Xiangyu; Kim, Rathana; Fernandes, Marta B; Raposo, Beatriz; Oliveira, Mariana L; Ribeiro, Daniel; Fragoso, Rita; Zenatti, Priscila P; Soares, Tiago; de Matos, Mafalda R; Corrêa, Juliana Ronchi; Duque, Mafalda; Roberts, Kathryn G; Gu, Zhaohui; Qu, Chunxu; Pereira, Clara; Pyne, Susan; Pyne, Nigel J; Barreto, Vasco M; Bernard-Pierrot, Isabelle; Clappier, Emannuelle; Mullighan, Charles G; Grosso, Ana R; Yunes, J Andrés; Barata, João T.
Afiliação
  • Almeida ARM; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Neto JL; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Cachucho A; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Euzébio M; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Meng X; Centro Infantil Boldrini, Campinas, SP, Brazil.
  • Kim R; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, Paris, France.
  • Fernandes MB; Hematology Laboratory, Saint-Louis Hospital, AP-HP, Paris, France, and Saint-Louis Research Institute, Université de Paris, INSERM U944/Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 7212, Paris, France.
  • Raposo B; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Oliveira ML; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Ribeiro D; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Fragoso R; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Zenatti PP; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Soares T; Centro Infantil Boldrini, Campinas, SP, Brazil.
  • de Matos MR; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Corrêa JR; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Duque M; Centro Infantil Boldrini, Campinas, SP, Brazil.
  • Roberts KG; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Gu Z; Department of Pathology and Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN, US.
  • Qu C; Department of Pathology and Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN, US.
  • Pereira C; Department of Pathology and Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN, US.
  • Pyne S; Smurfit Institute of Genetics, Trinity College Dublin, University of Dublin, Dublin 2, Ireland.
  • Pyne NJ; Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow, Scotland, UK.
  • Barreto VM; Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow, Scotland, UK.
  • Bernard-Pierrot I; DNA Breaks Laboratory, CEDOC - Chronic Diseases Research Center, NOVA Medical School - Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal.
  • Clappier E; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, Paris, France.
  • Mullighan CG; Hematology Laboratory, Saint-Louis Hospital, AP-HP, Paris, France, and Saint-Louis Research Institute, Université de Paris, INSERM U944/Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 7212, Paris, France.
  • Grosso AR; Department of Pathology and Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN, US.
  • Yunes JA; UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica, Portugal.
  • Barata JT; Centro Infantil Boldrini, Campinas, SP, Brazil. andres@boldrini.org.br.
Nat Commun ; 12(1): 7268, 2021 12 14.
Article em En | MEDLINE | ID: mdl-34907175
Interleukin-7 receptor α (encoded by IL7R) is essential for lymphoid development. Whether acute lymphoblastic leukemia (ALL)-related IL7R gain-of-function mutations can trigger leukemogenesis remains unclear. Here, we demonstrate that lymphoid-restricted mutant IL7R, expressed at physiological levels in conditional knock-in mice, establishes a pre-leukemic stage in which B-cell precursors display self-renewal ability, initiating leukemia resembling PAX5 P80R or Ph-like human B-ALL. Full transformation associates with transcriptional upregulation of oncogenes such as Myc or Bcl2, downregulation of tumor suppressors such as Ikzf1 or Arid2, and major IL-7R signaling upregulation (involving JAK/STAT5 and PI3K/mTOR), required for leukemia cell viability. Accordingly, maximal signaling drives full penetrance and early leukemia onset in homozygous IL7R mutant animals. Notably, we identify 2 transcriptional subgroups in mouse and human Ph-like ALL, and show that dactolisib and sphingosine-kinase inhibitors are potential treatment avenues for IL-7R-related cases. Our model, a resource to explore the pathophysiology and therapeutic vulnerabilities of B-ALL, demonstrates that IL7R can initiate this malignancy.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Subunidade alfa de Receptor de Interleucina-7 Limite: Animals / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Portugal

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Subunidade alfa de Receptor de Interleucina-7 Limite: Animals / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Portugal